REGENXBIO Inc. (RGNX): director Daniel Tassé reason not stated

RGNX · Nasdaq · Biological Products, (No Diagnostic Substances) · Non-accelerated filer<br>Smaller reporting company · MD · Form 8-K filed 2026-10-16

Kenneth T. Mills resigned from the board effective October 21, 2026; George Migausky appointed Chairman; Daniel Tassé stepped down as Lead Independent Director.

Open seatNo successor namedEffective within 30 daysBoard electionNo reason given

Events in this filing

3 events: Departure (Director), Board election (Chair), Departure (Director).

Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans

Item 5.02 as filed

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role. Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.
In connection with Mr. Mills’ departure, the Board appointed George Migausky as Chairman of the Board (“Chairman”). In accordance with the Company’s Corporate Governance Guidelines, Daniel Tassé has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board.

Source filing on EDGAR →